Voyager Therapeutics Files 8-K
Ticker: VYGR · Form: 8-K · Filed: May 16, 2024 · CIK: 1640266
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Voyager Therapeutics filed an 8-K on May 16, 2024, for 'Other Events'.
AI Summary
On May 16, 2024, Voyager Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding new agreements, financial transactions, or significant corporate changes were provided in the excerpt.
Why It Matters
This filing signals that Voyager Therapeutics has made a regulatory disclosure. Investors should review the full filing for details on any material events that could impact the company's stock.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific financial or operational details that would indicate immediate risk.
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Registrant
- May 16, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report "Other Events" as of May 16, 2024.
What is the exact name of the reporting company?
The exact name of the reporting company is Voyager Therapeutics, Inc.
In which state was Voyager Therapeutics, Inc. incorporated?
Voyager Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Voyager Therapeutics, Inc.?
The principal executive office address is 75 Hayden Avenue, Lexington, Massachusetts, 02421.
What is the telephone number for Voyager Therapeutics, Inc.?
The telephone number for Voyager Therapeutics, Inc. is (857) 259-5340.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-05-16 07:05:52
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value VYGR Nasdaq Global Select M
Filing Documents
- tm2414591d1_8k.htm (8-K) — 25KB
- 0001104659-24-062257.txt ( ) — 193KB
- vygr-20240516.xsd (EX-101.SCH) — 3KB
- vygr-20240516_lab.xml (EX-101.LAB) — 33KB
- vygr-20240516_pre.xml (EX-101.PRE) — 22KB
- tm2414591d1_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events On May 16, 2024, Voyager Therapeutics, Inc. announced that the first participants were dosed in a Phase 1a single ascending dose ("SAD") trial of VY-TAU01, an investigational anti-tau antibody developed to inhibit the spread of pathological tau in Alzheimer's disease. The objective of the randomized, double-blind, placebo-controlled, SAD trial is to evaluate the safety and pharmacokinetics of VY-TAU01 in healthy adult volunteers. The study is being conducted at a single site in the United States and is expected to enroll approximately 48 patients in multiple cohorts. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 16 , 2024 VOYAGER THERAPEUTICS, INC. By: /s/ Alfred Sandrock, M.D., Ph.D. Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director (Principal Executive Officer) 3